All News

Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress.

Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early adverse effect management for patients starting zongertinib (Hernexeos).

Plasma proteomics revolutionizes treatment for triple-negative breast cancer, offering predictive insights and new therapeutic strategies through the innovative PIPscore.

Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).

E. Camille Vaughan, MD, MS, addresses how state-level differences and potential new prescription requirements could impact patient access to COVID-19 vaccines this fall.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the challenges of managing myelofibrosis, from its heterogeneity and symptom burden to limited curative options.

Health officials warn of rising Chagas disease cases in the US, linked to kissing bugs and the parasite Trypanosoma cruzi, urging public awareness.

The trial results, which showed baxdrostat significantly reduced mean seated systolic blood pressure in uncontrolled hypertension, were presented at the 2025 European Society of Cardiology Congress.

FDA expands Vonvendi use for von Willebrand disease (VWD), enhancing treatment options for adults and children to manage bleeding effectively.

Both cemdisiran alone and combined with pozelimab improved the Myasthenia Gravis Activities of Daily Living score in patients with generalized myasthenia gravis.

Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).

Susan Cantrell, RPh, MHL, CAE, CEO of the Academy of Managed Care Pharmacy (AMCP), warns that politicizing the Advisory Committee on Immunization Practices (ACIP) could undermine vaccine trust.

Pavblu, a biosimilar to Eylea, also showed no clinically meaningful differences in efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).

New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.

The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

E. Camille Vaughan, MD, MS, highlights the key role pharmacists play in providing clear, trusted guidance for patients seeking COVID-19 vaccines this fall.

A chief pharmacy officer emphasizes the vital role of pharmacists in enhancing patient care, advocating for recognition, and integration within health care systems.

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

Compared with docetaxel, adagrasib shows significant progression-free survival (PFS) benefits in patients with non–small cell lung cancer (NSCLC).

This milestone celebration not only honors CPA’s legacy but also underscores the profession’s future—one defined by collaboration, innovation, and a steadfast commitment to patient care.

FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.

Individuals with learning disabilities face a heightened risk of severe type 2 diabetes (T2D), leading to increased mortality despite better glycemic control.

New findings suggest high-dose influenza vaccines offer better protection against the flu and reduce cardiac complications in older adults.

Katherine Saunders, MD, weighs in on orforglipron’s potential to expand obesity treatment options, improve adherence with a simple oral regimen, and address barriers to care and access.

Pharmacies increasingly dispense buprenorphine, enhancing access to opioid addiction treatment while embracing AI and telepharmacy innovations for better care.

A single dose of an RSV vaccine significantly reduces hospitalization risk for older adults, offering protection for 2 seasons against severe infections.

GLP-1 medications like semaglutide and tirzepatide significantly lower heart failure hospitalization risks, expanding treatment options for obesity-related conditions.